HHS Revives Controversial Data-Tracking Program for Autism Surveillance, Senate Warns

The Revival of a Controversial Data Project Under a New Name

A recent report from the Senate Appropriations Committee has raised concerns about a project that appears to be a rebranded version of a previously abandoned initiative. This time, instead of focusing on Alzheimer’s disease, it aims to study autism. The project, led by the National Institutes of Health (NIH), has sparked debates over data privacy, project management, and the use of federal funds.

The original project, which was aimed at creating a “real-world data platform” for monitoring Alzheimer’s, was shut down in 2024 after facing criticism from Congress and watchdog agencies. A report by the Government Accountability Office (GAO) highlighted serious issues with its management, including the risk of mismanaging hundreds of millions of dollars and failing to address privacy concerns. Despite these red flags, the NIH is now attempting to revive the same concept under a different name, this time focused on autism research.

This revival comes as part of a broader initiative led by Health and Human Services Secretary Robert F. Kennedy Jr., who has made autism a priority. His plan involves creating a comprehensive database to better understand the causes of autism. While HHS claims the initiative is not a “registry,” some experts and advocacy groups are skeptical. They worry that the project could lead to the collection of sensitive personal data without adequate safeguards.

The Role of Palantir and Data Privacy Concerns

One of the most controversial aspects of the revived project is the involvement of Palantir, a data analytics company co-founded by billionaire Peter Thiel. Palantir has been heavily involved in government contracts, particularly under the Trump administration. Its technology has been used in various sectors, including healthcare and national security. The company’s role in the new autism initiative raises questions about how data will be collected, stored, and used.

The project is expected to use a platform called N3C, originally developed by Palantir for COVID-19 research. The system has since been adapted for other purposes, including cancer research. However, critics argue that using such a platform for large-scale data collection poses significant risks, especially when it comes to protecting individuals’ privacy.

Autism advocates have expressed concerns that the data collected could be used in ways that harm the community. For example, there are fears that the information could be shared with law enforcement or other entities that may not be trustworthy. Even if the data is anonymized, experts warn that it can often be traced back to individuals through basic demographic information.

Congressional Pushback and Bipartisan Concerns

The Senate Appropriations Committee has voiced strong concerns about the project, calling it “nearly identical” to the previous Alzheimer’s effort. In a document released last week, the committee urged the NIH to pause funding any new awards related to the project and to provide regular updates to congressional committees.

This pushback is not limited to one political party. Both Republican and Democratic members of the Senate have expressed reservations about the initiative, suggesting that the concerns are bipartisan. The report highlights the need for transparency and accountability, especially given the history of mismanagement associated with similar projects.

Despite these warnings, the NIH continues to move forward with the project, setting aggressive timelines for its implementation. According to internal documents obtained by TPM, the platform is expected to be up and running within four months. However, it remains unclear whether the agency has addressed the concerns that led to the original project’s shutdown.

The Debate Over Autism Research

While the initiative is framed as a way to advance autism research, many scientists question its necessity and potential impact. Some argue that the focus should be on improving existing support systems rather than collecting vast amounts of data. Others worry that the project could divert resources away from more effective research methods.

Dr. Helen Tager-Flusberg, a prominent autism researcher, has criticized the approach, stating that current research suggests autism is rooted in genetic factors and early prenatal development. She also raised concerns about the feasibility of the project, noting that even anonymized data can be linked back to individuals.

As the project moves forward, the debate over its purpose, methodology, and ethical implications is likely to continue. With the involvement of high-profile figures and a powerful data contractor, the initiative has become a focal point for discussions about privacy, transparency, and the future of medical research.